Table 3.
Drug | Authors | Animal/cell | Disease model | Administration | Effects | Signaling pathways |
---|---|---|---|---|---|---|
HRS | Sun et. al 201121 | C57BL/6 mice | Septic liver injury (GalN/LPS) | HRS 8ml/kg/3h × 3 i.p. | TUNEL (+)↓, caspase-3 ↓, cPARP ↓ | ROS-JNK-Caspase3 ↓ |
2% H2 | Qiu et. al 201113 | C57BL/6 mice | Septic lung injury (LPS) | 2% H2 inhalation | TUNEL (+) ↓, Bax ↓, caspase-3↓, Bcl-xl ↑ | ROS-JNK-Caspase3 ↓ |
HRS 2% H2 |
Xie et. al 20128 | C57BL/6 mice | Septic lung injury (LPS) | 2% H2 inhalation/HRS 10 ml/kg i.p. | TUNEL (+) ↓, caspase-3 ↓ | NF-κB ↓ |
HRS | Zhou et. al 2012113 | Wistar rats | Sepsis (CLP) | HRS 2.5 or 10 ml/kg i.p. | TUNEL (+) ↓, caspase-3 ↓ | N/A |
HRS | Li et. al 201323 | Sprague-Dawley rats | Sepsis (CLP) | HRS 5 ml/kg i.p. | TUNEL (+) ↓ | N/A |
HRS | Xu et. al 201322 | Sprague-Dawley rats | Septic liver injury (LPS) | HRS 8 ml/kg/h i.v.× 6h | TUNEL (+) ↓, Smac ↓, caspase-3 ↓ | NF-κB ↓, Smac ↓, MAPK (JNK/P38) ↓ |
2% H2 | Liu et. al 201426 | ICR mice | Septic brain injury (CLP) | Inhale 2% H2 1h (post-operation 1h and 6h) | TUNEL (+) ↓ | Nrf2/HO-1 ↑ |
HRS HRM |
Chen et. al 201536 | ICR mice, UVECs-12 | Sepsis (CLP) HUVECs (LPS) |
HRS 5 ml/kg i.p., HRM 0.6 mmol/L | Annexin-V/PI ↓, caspase-3 ↓ | Nrf2/HO-1 ↑ |
HRS | Zhang et. al 201511 | Sprague-Dawley rats | Septic lung injury (LPS) | HRS 8 ml/kg/h i.v.× 6h | TUNEL (+) ↓, caspase-3 ↓ | P38 MAPK ↓ |
HW | Iketani et. al 20176 | C57BL/6 mice | Sepsis (LPS) | HW oral (72h before and after LPS) | TUNEL (+) ↓ | HO-1 ↑, ET-1 ↑ |
HRS: hydrogen rich saline, HRM: hydrogen rich medium, HW: hydrogen water, LPS: Lipopolysaccharide, CLP: cecal ligation and puncture, GalN: D-galactosamine, i.p.: Intraperitoneal injection, i.v.: Intravenous injection, TUNEL: terminal deoxynucleotidyl transferase mediated dUTP nick end labeling, cPARP: cytoplasm poly ADP-ribose polymerase, ROS: reactive oxygen species, Smac: second mitochondria-derived activator of caspases.